![]() | |
Type | Public limited company |
---|---|
LSE: NIOX | |
Industry | Medical Devices |
Founded | 2006 [1] |
Founders | Steve Harris and Charles Swingland [1] |
Headquarters | Oxford, United Kingdom |
Key people | Ian Johnson (Executive Chairman) Michael Roller (CFO) Jonathan Emms (COO) |
Revenue | £23.9 million (2020) [2] |
£(17.3) million (2020) [2] | |
£(33.5) million (2020) [2] | |
Website | www.niox.com |
NIOX Group PLC is a company focussed on treating people suffering from respiratory diseases through its NIOX (Nitric Oxide) range of FeNO (Fractional Exhaled Nitric Oxide) devices which help diagnose and manage asthma. [3] The company is a provider of point-of-care FeNO (Fractional Exhaled Nitric Oxide) measurement and monitoring. [3] It is listed on the London Stock Exchange.
The company was founded by Steve Harris and Charles Swingland as Circassia Group in 2006. [1] It was the subject of an initial public offering in March 2014. [4]
In December 2019, Steve Harris announced that he was resigning as CEO of the company. Ian Johnson took over as Executive Chairman of the company, Michael Roller replaced Julien Cotta as the Chief Financial Officer, and Jonathan Emms, who was appointed to the company in September 2019, became the Chief Operating Officer. [5]
The company also announced its withdrawal from the COPD (chronic obstructive pulmonary disease) business in April 2020, with a proposed transfer of assets to, and termination of agreement with, AstraZeneca for consideration to be set off against debt and accrued interest. [6]
In 2022 the company changed its name from Circassia Group plc to NIOX Group plc. [7]
NIOX Group has direct offices in the United Kingdom, United States, Germany, Sweden and China. The company also operates through a distribution model, working with partner companies in order make NIOX available throughout the globe. [8]
NIOX (Nitric Oxide) is a FeNO testing device. Using visual aids and sounds, NIOX provides an easy to use test experience to help patients perform FeNO (Fractional Exhaled Nitric Oxide) tests. [9]
FeNO aids healthcare professionals with the diagnosis and management of asthma. [9]
Nitric oxide is a colorless gas with the formula NO. It is one of the principal oxides of nitrogen. Nitric oxide is a free radical: it has an unpaired electron, which is sometimes denoted by a dot in its chemical formula. Nitric oxide is also a heteronuclear diatomic molecule, a class of molecules whose study spawned early modern theories of chemical bonding.
Nitrogen dioxide is a chemical compound with the formula NO2 and is one of several nitrogen oxides. NO2 is an intermediate in the industrial synthesis of nitric acid, millions of tons of which are produced each year for use. At higher temperatures, nitrogen dioxide is a reddish-brown gas. Nitrogen dioxide is a paramagnetic, bent molecule with C2v point group symmetry.
Eno may refer to:
Spirometry is the most common of the pulmonary function tests (PFTs). It measures lung function, specifically the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Spirometry is helpful in assessing breathing patterns that identify conditions such as asthma, pulmonary fibrosis, cystic fibrosis, and COPD. It is also helpful as part of a system of health surveillance, in which breathing patterns are measured over time.
Medtronic plc is an American medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
A breath test is a type of test performed on air generated from the act of exhalation.
Gasotransmitters is a class of neurotransmitters. The molecules are distinguished from other bioactive endogenous gaseous signaling molecules based on a need to meet distinct characterization criteria. Currently, only nitric oxide, carbon monoxide, and hydrogen sulfide are accepted as gasotransmitters.
A nitrate test is a chemical test used to determine the presence of nitrate ion in solution. Testing for the presence of nitrate via wet chemistry is generally difficult compared with testing for other anions, as almost all nitrates are soluble in water. In contrast, many common ions give insoluble salts, e.g. halides precipitate with silver, and sulfate precipitate with barium.
Endothelial NOS (eNOS), also known as nitric oxide synthase 3 (NOS3) or constitutive NOS (cNOS), is an enzyme that in humans is encoded by the NOS3 gene located in the 7q35-7q36 region of chromosome 7. This enzyme is one of three isoforms that synthesize nitric oxide (NO), a small gaseous and lipophilic molecule that participates in several biological processes. The other isoforms include neuronal nitric oxide synthase (nNOS), which is constitutively expressed in specific neurons of the brain and inducible nitric oxide synthase (iNOS), whose expression is typically induced in inflammatory diseases. eNOS is primarily responsible for the generation of NO in the vascular endothelium, a monolayer of flat cells lining the interior surface of blood vessels, at the interface between circulating blood in the lumen and the remainder of the vessel wall. NO produced by eNOS in the vascular endothelium plays crucial roles in regulating vascular tone, cellular proliferation, leukocyte adhesion, and platelet aggregation. Therefore, a functional eNOS is essential for a healthy cardiovascular system.
Nitric oxide synthase 1 (neuronal), also known as NOS1, is an enzyme that in humans is encoded by the NOS1 gene.
In medicine, exhaled nitric oxide (eNO) can be measured in a breath test for asthma and other respiratory conditions characterized by airway inflammation. Nitric oxide (NO) is a gaseous molecule produced by certain cell types in an inflammatory response. The fraction of exhaled NO (FENO) is a promising biomarker for the diagnosis, follow-up and as a guide to therapy in adults and children with asthma. The breath test has recently become available in many well-equipped hospitals in developed countries, although its exact role remains unclear.
Biological functions of nitric oxide are roles that nitric oxide plays within biology.
Vectura Group Limited is a British pharmaceuticals company based in Chippenham, England which develops inhaled medicines and makes inhaler devices. The company was listed on the London Stock Exchange until it was acquired by Philip Morris International in September 2021.
Exhaled breath condensate (EBC) is the exhalate from breath, that has been condensed, typically via cooling using a collection device. EBC reflects changes in the respiratory fluid that lines the airways and is an inexpensive, non-invasive tool that has potential for scientific research. Despite its promises, it has not been proven for screening or diagnosing diseases of the lung and other conditions, yet. It has long been appreciated that the exhaled breath is saturated by water vapour, but using it for studies of the lung was probably first described in the Russian scientific literature.
Breath gas analysis is a method for gaining information on the clinical state of an individual by monitoring volatile organic compounds (VOCs) present in the exhaled breath. Exhaled breath is naturally produced by the human body through expiration and therefore can be collected in non-invasively and in an unlimited way. VOCs in exhaled breath can represent biomarkers for certain pathologies. Breath gas concentration can then be related to blood concentrations via mathematical modeling as for example in blood alcohol testing. There are various techniques that can be employed to collect and analyze exhaled breath. Research on exhaled breath started many years ago, there is currently limited clinical application of it for disease diagnosis. However, this might change in the near future as currently large implementation studies are starting globally.
Sir Peter John Barnes, FRCP, FCCP, FMedSci, FRS is a British respiratory scientist and clinician, a specialist in the mechanisms and treatment of asthma and chronic obstructive pulmonary disease (COPD). He was Margaret Turner-Warwick Professor of Thoracic Medicine at the National Heart & Lung Institute, previous head of respiratory medicine at Imperial College and honorary consultant physician at the Royal Brompton Hospital London. He is one of the most highly cited scientists in the world
Sodium nitroprusside (SNP), sold under the brand name Nitropress among others, is a medication used to lower blood pressure. This may be done if the blood pressure is very high and resulting in symptoms, in certain types of heart failure, and during surgery to decrease bleeding. It is used by continuous injection into a vein. Onset is nearly immediate and effects last for up to ten minutes.
GLOBO plc provides enterprise mobility management (EMM) and mobile application development (MADP) software and services. Globo was listed on the London Stock Exchange's AIM market (GBO: LN)"Share price information". Retrieved 27 January 2015. Globo acquired Notify Technology in October 2013, adding Mobile Device Management (MDM) capabilities to its EMM product offering and expanding its operations in the USA. In June 2014, Globo acquired Sourcebits, a designer and developer of apps.
Katrina Miranda is an associate professor of biochemistry at the University of Arizona. She works on nitric oxide and their role in diseases like breast cancer, stroke and chronic pain.
A coronavirus breathalyzer is a diagnostic medical device enabling the user to test with 90% or greater accuracy the presence of severe acute respiratory syndrome coronavirus 2 in an exhaled breath. As of the first half of 2020, the idea of a practical coronavirus breathalyzer was concomitantly developed by unrelated research groups in Australia, Canada, Finland, Germany, Indonesia, Israel, Netherlands, Poland, Singapore, United Kingdom and USA.